{"Symbol": "ACRV", "AssetType": "Common Stock", "Name": "Acrivon Therapeutics, Inc. Common Stock", "Description": "Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of precision cancer medicines. The company is headquartered in Watertown, Massachusetts.", "CIK": "1781174", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "480 ARSENAL WAY, WATERTOWN, MA, UNITED STATES, 02472", "OfficialSite": "https://acrivon.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "51435000", "EBITDA": "-87654000", "PERatio": "None", "PEGRatio": "None", "BookValue": "4.076", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-2.12", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.309", "ReturnOnEquityTTM": "-0.502", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-2.12", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "11.5", "AnalystRatingStrongBuy": "3", "AnalystRatingBuy": "5", "AnalystRatingHold": "1", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "0.405", "EVToRevenue": "-", "EVToEBITDA": "-0.427", "Beta": "1.757", "52WeekHigh": "6.08", "52WeekLow": "1.05", "50DayMovingAverage": "2.113", "200DayMovingAverage": "1.688", "SharesOutstanding": "31555100", "SharesFloat": "16788000", "PercentInsiders": "20.567", "PercentInstitutions": "57.682", "DividendDate": "None", "ExDividendDate": "None"}